BELLUS Health Inc.
BLU
$0.01
Change (1 day)
$14.76
Year High
$6.38
Year Low
Categories
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.
P/B ratio for BELLUS Health Inc. (BLU)
P/B ratio as of 2022: 2.43
According to BELLUS Health Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.43. At the end of 2021 the company had a P/B ratio of 2.19.
P/B ratio history for BELLUS Health Inc. from 1999 to 2022
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2022 | 2.43 |
| 2021 | 2.19 |
| 2020 | 1.23 |
| 2019 | 32.94 |
| 2018 | 3.43 |
| 2017 | 1.28 |
| 2016 | 2.69 |
| 2015 | 7.47 |
| 2014 | 8.70 |
| 2013 | 2.17 |
| 2012 | 1.40 |
| 2011 | -0.29 |
| 2010 | -21.31 |
| 2009 | -25.18 |
| 2008 | -3.54 |
| 2007 | 58.33 |
| 2006 | -156.04 |
| 2005 | 5.81 |
| 2004 | 7.15 |
| 2003 | 4.07 |
| 2001 | 8.86 |
| 2000 | 5.70 |
| 1999 | 4.60 |